News Releases
Amendment to the Dory Property Option Agreement
Vancouver, British Columbia – TheNewswire – May 31, 2023 – Lexston Life Sciences Corp. (the “Company”) (CSE:LEXT) (OTC:LEXTF) and the optionor…
 |
|||||||||
Vancouver, British Columbia – TheNewswire – May 31, 2023 – Lexston Life Sciences Corp. (the “Company”) (CSE:LEXT) (OTC:LEXTF) and the optionor amended the Dory Property Option Agreement dated for reference January 18, 2023 (the “Dory Property Option Agreement”). Pursuant to the amendment (“Amendment 1”), section 3.2 of the Dory Property Option Agreement was replaced with the following text:
“3.2 In order to exercise the Option and earn the first Fifty One Percent (51%) interest in the Property, the Optionee, within six months from the date of the acceptance by the Exchange of this Agreement and the change of business of the Optionee, has to:
a) pay to the Optionor Eighty Five Thousand Dollars ($85,000); and
b) issue to the Optionor a total of Two Hundred and Fifty Thousand (250,000) Shares.
Upon satisfaction of the conditions set out in this Section 3.2, the Option with respect to the 51% interest in the Property shall be deemed to be exercised, and an undivided 51% right, title and interest in the Property will automatically vest in the Optionee and the Optionor shall promptly register the 51% interest in the Property in the name of the Optionee, with the applicable registration fees and costs to be borne by the Optionee.”
The Dory Property Option Agreement and Amendment 1 are available on www.sedar.com under the profile of the Company.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal, Chief Executive Officer
Telephone: (604) 928-8913
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Copyright (c) 2023 TheNewswire – All rights reserved.
cse
canadian securities exchange
otc
cse-lext
lexston-life-sciences-corp
press-release
nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) Announces an Expansion of its YMI Validation Project
Calgary, Alberta – TheNewswire – October 17, 2023 – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces an expansion…
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved
TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple MyelomaToronto, Ontario–(Newsfile Corp. – October 17, 2023) – Telo Genomics…
NervGen Pharma Appoints John Ruffolo to Board of Directors
Extensive experience in private equity, venture capital and advising high growth, innovative companiesBrings personal experience and knowledge of spinal…
